Glutamic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Glutamic Acid: From Amino Acid Supplement to Postmenopausal Osteoporosis
One-Sentence Summary
Glutamic acid is a naturally occurring amino acid that serves as a substrate for vitamin K-dependent γ-carboxylation of bone proteins such as osteocalcin, making it a metabolic player in bone mineralization. The TxGNN model predicts it may be effective for Postmenopausal Osteoporosis, with 1 Phase 3 clinical trial and 11 publications currently supporting this direction — though most evidence is mechanistic or indirect. The strongest direct evidence comes from an animal study (ovariectomized mice) and a human calcium absorption study using poly-γ-glutamic acid.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record; used as a nutritional amino acid |
| Predicted New Indication | Postmenopausal Osteoporosis |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L3 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Glutamic acid (Glu) is a non-essential amino acid and the most abundant excitatory neurotransmitter in the central nervous system. In bone biology, however, its role is quite distinct: glutamic acid residues embedded in bone matrix proteins — most notably osteocalcin and Matrix Gla Protein (MGP) — undergo vitamin K-dependent γ-carboxylation, converting Glu to γ-carboxyglutamic acid (Gla). Gla-osteocalcin is a critical regulator of hydroxyapatite binding and bone mineralization. This biochemical pathway connects glutamic acid availability directly to bone matrix quality.
Postmenopausal osteoporosis is characterized by accelerated bone resorption driven by estrogen deficiency, leading to under-carboxylated osteocalcin and impaired bone mineralization. PMID 26144993 directly demonstrated that exogenous glutamic acid administration improved bone metabolism and attenuated menopausal-like symptoms in ovariectomized mice — providing the most direct preclinical evidence. Additionally, PMID 18187428 showed that poly-γ-glutamic acid (PGA) acutely increased calcium absorption in postmenopausal women in a human feeding study, suggesting a plausible dietary intervention pathway.
The existing clinical literature on this indication largely examines related agents (vitamin K2, bisphosphonates) that work upstream or downstream of the same Gla-protein pathway. While these trials do not directly test glutamic acid, they reinforce the biological plausibility of the Glu → Gla → osteocalcin axis as a therapeutic target. The key limitation is the complete absence of dedicated clinical trials testing glutamic acid supplementation in postmenopausal osteoporosis, leaving the evidence predominantly at the mechanistic and preclinical level.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00048061 | Phase 3 | Completed | 1,609 | Large RCT comparing different oral ibandronate regimens in postmenopausal osteoporosis; patients also received vitamin D and calcium supplementation. Drug tested is ibandronate (bisphosphonate), not glutamic acid directly — included as same-indication reference trial. |
Note: No clinical trials directly testing glutamic acid in postmenopausal osteoporosis were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26144993 | 2015 | Animal study (in vivo) | Nutrition Research | Most directly relevant. Glutamic acid administration improved bone metabolism and menopausal-like symptoms in ovariectomized mice, suggesting an estrogenic or bone-protective effect. |
| 18187428 | 2007 | Clinical intervention | J Am Coll Nutrition | Poly-γ-glutamic acid (PGA) acutely increased calcium absorption in postmenopausal women — first human evidence of glutamate-related compound improving bone mineral homeostasis. |
| 14529146 | 2003 | RCT | Keio J Medicine | Vitamin K2 (menatetrenone) enhances γ-carboxylation of bone glutamic acid residues (osteocalcin), sustains lumbar BMD, and prevents fractures in postmenopausal women. Mechanistically links glutamic acid substrate to bone outcomes. |
| 14584089 | 2003 | RCT | Yonsei Med J | Combined vitamin K2 + bisphosphonate therapy in postmenopausal osteoporosis; vitamin K2 function explicitly attributed to γ-carboxylation of glutamic acid residues in osteocalcin. |
| 29437025 | 2018 | Genetic association | Endocr Metab Immune Disord | VKORC1 gene polymorphism affects vitamin K-dependent γ-carboxylation of glutamic acid residues; variation associated with osteoporosis risk in postmenopausal women. |
| 40950804 | 2025 | Metabolomics/Cohort | J Diabetes Metab Disord | Serum amino acid profiles (including glutamic acid) associated with aging and sex hormone levels in elderly population; provides metabolomic context for postmenopausal changes. |
| 19172219 | 2009 | RCT | J Bone Miner Metab | 6-month randomized study showing menatetrenone increases γ-carboxylation of osteocalcin (Gla formation from glutamic acid residues) with modest effects on bone turnover markers. |
| 11668761 | 2001 | Observational | Tidsskr Nor Laegeforen | Dietary vitamin K intake in Norwegian diet linked to glutamic acid carboxylation and bone health; observational context for nutritional interventions. |
| 34529430 | 2021 | Preclinical/Drug delivery | Nano Letters | Bone-targeting polymer vesicle using poly(l-glutamic acid) block for targeted estradiol delivery to bone; demonstrates glutamic acid polymer as bone-targeting vehicle. |
Singapore Market Information
Glutamic acid (DB00142) currently has no registered products in Singapore. It is not marketed as a pharmaceutical drug in this jurisdiction.
Safety Considerations
Safety information for glutamic acid as a pharmaceutical intervention is not available in the current evidence pack. Please refer to the package insert and standard pharmacopoeial monographs for safety information. As a naturally occurring amino acid abundant in dietary protein, it has an established safety profile at nutritional doses; however, pharmacological dosing for osteoporosis would require dedicated safety evaluation.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The TxGNN prediction is mechanistically grounded — glutamic acid residues in osteocalcin are essential for bone mineralization via the vitamin K-dependent Gla pathway — and is supported by one direct animal study and a human calcium absorption trial. However, there are no completed clinical trials testing glutamic acid itself in postmenopausal osteoporosis, placing this firmly at a research hypothesis stage rather than a clinical readiness stage.
To proceed, the following is needed:
- Proof-of-concept human study: A small Phase 1/2 trial testing oral glutamic acid supplementation on osteocalcin carboxylation status and bone turnover markers (CTx, P1NP) in postmenopausal women.
- Dose-ranging and formulation work: Establish pharmacokinetically relevant oral doses that measurably increase circulating glutamic acid, given efficient dietary and first-pass metabolism.
- Mechanistic validation: Clarify whether supplemental glutamic acid increases Gla-osteocalcin in vitamin K-replete subjects, or only in those with suboptimal vitamin K status.
- Biomarker endpoint selection: Define surrogate endpoints (undercarboxylated osteocalcin ratio, serum Gla-OC) that can serve as go/no-go signals before a full fracture-endpoint trial.
- Regulatory pathway review: Confirm whether glutamic acid would be regulated as a nutraceutical or pharmaceutical in Singapore, which determines the development pathway and evidentiary requirements.
- Safety monitoring plan: Establish safety monitoring for gastrointestinal tolerability and plasma glutamate levels, particularly in subjects with neurological comorbidities where glutamate excitotoxicity is a concern.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.